Jasper Therapeutics Analyst Ratings
Jasper Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 187.77% | Credit Suisse | → $4 | Reiterates | Outperform → Outperform |
| 08/11/2023 | 403.6% | Capital One | → $7 | Initiates Coverage On | → Overweight |
| 06/12/2023 | 392.81% | EF Hutton | → $6.85 | Reiterates | Buy → Buy |
| 05/25/2023 | 392.81% | EF Hutton | → $6.85 | Assumes | → Buy |
| 05/16/2023 | 475.54% | Oppenheimer | → $8 | Reinstates | Outperform → Outperform |
| 05/15/2023 | 392.81% | EF Hutton | → $6.85 | Reiterates | Buy → Buy |
| 05/15/2023 | 187.77% | Credit Suisse | → $4 | Reiterates | Outperform → Outperform |
| 03/09/2023 | 392.81% | EF Hutton | → $6.85 | Reiterates | → Buy |
| 03/09/2023 | 331.65% | Cantor Fitzgerald | → $6 | Reiterates | → Overweight |
| 03/09/2023 | 187.77% | Credit Suisse | → $4 | Reiterates | → Outperform |
| 02/27/2023 | 392.81% | EF Hutton | → $6.85 | Reiterates | → Buy |
| 02/21/2023 | 392.81% | EF Hutton | → $6.85 | Reiterates | → Buy |
| 02/17/2023 | 392.81% | EF Hutton | → $6.85 | Reiterates | → Buy |
| 02/16/2023 | 392.81% | EF Hutton | $4 → $6.85 | Maintains | Buy |
| 02/07/2023 | 331.65% | Cantor Fitzgerald | $10 → $6 | Reiterates | → Overweight |
| 01/11/2023 | 115.83% | Credit Suisse | $7 → $3 | Maintains | Outperform |
| 01/11/2023 | 187.77% | EF Hutton | → $4 | Maintains | Buy |
| 11/14/2022 | 475.54% | Oppenheimer | $21 → $8 | Maintains | Outperform |
| 11/01/2022 | 187.77% | EF Hutton | → $4 | Initiates Coverage On | → Buy |
| 07/13/2022 | 475.54% | Credit Suisse | $9 → $8 | Maintains | Outperform |
| 05/13/2022 | 547.48% | Credit Suisse | $10 → $9 | Maintains | Outperform |
| 02/28/2022 | 619.42% | Cantor Fitzgerald | → $10 | Initiates Coverage On | → Overweight |
| 02/25/2022 | 619.42% | Credit Suisse | $15 → $10 | Maintains | Outperform |
| 11/08/2021 | 979.14% | Credit Suisse | → $15 | Initiates Coverage On | → Outperform |
| 10/21/2021 | — | William Blair | Initiates Coverage On | → Outperform | |
| 10/20/2021 | 1266.91% | BMO Capital | → $19 | Initiates Coverage On | → Outperform |
| 10/13/2021 | 1410.79% | Oppenheimer | → $21 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月14日 | 187.77% | 瑞士信貸 | →$4 | 重申 | 跑贏→跑贏大盤 |
| 2023年08月11日 | 403.6% | 大寫一 | →$7 | 開始承保 | →超重 |
| 2023/06/12 | 392.81% | EF Hutton | →$6.85 | 重申 | 購買→購買 |
| 2023年05月25日 | 392.81% | EF Hutton | →$6.85 | 假設 | →購買 |
| 2023年05月16日 | 475.54% | 奧本海默 | →$8 | 恢復 | 跑贏→跑贏大盤 |
| 2023年05月15日 | 392.81% | EF Hutton | →$6.85 | 重申 | 購買→購買 |
| 2023年05月15日 | 187.77% | 瑞士信貸 | →$4 | 重申 | 跑贏→跑贏大盤 |
| 03/09/2023 | 392.81% | EF Hutton | →$6.85 | 重申 | →購買 |
| 03/09/2023 | 331.65% | 康託·菲茨傑拉德 | →$6 | 重申 | →超重 |
| 03/09/2023 | 187.77% | 瑞士信貸 | →$4 | 重申 | →跑贏大盤 |
| 02/27/2023 | 392.81% | EF Hutton | →$6.85 | 重申 | →購買 |
| 02/21/2023 | 392.81% | EF Hutton | →$6.85 | 重申 | →購買 |
| 02/17/2023 | 392.81% | EF Hutton | →$6.85 | 重申 | →購買 |
| 02/16/2023 | 392.81% | EF Hutton | $4→$6.85 | 維護 | 買 |
| 02/07/2023 | 331.65% | 康託·菲茨傑拉德 | $10→$6 | 重申 | →超重 |
| 2023年1月11日 | 115.83% | 瑞士信貸 | $7→$3 | 維護 | 跑贏大盤 |
| 2023年1月11日 | 187.77% | EF Hutton | →$4 | 維護 | 買 |
| 2022年11月14日 | 475.54% | 奧本海默 | $21→$8 | 維護 | 跑贏大盤 |
| 11/01/2022 | 187.77% | EF Hutton | →$4 | 開始承保 | →購買 |
| 07/13/2022 | 475.54% | 瑞士信貸 | $9→$8 | 維護 | 跑贏大盤 |
| 2022年05月13日 | 547.48% | 瑞士信貸 | $10→$9 | 維護 | 跑贏大盤 |
| 02/28/2022 | 619.42% | 康託·菲茨傑拉德 | →$10 | 開始承保 | →超重 |
| 02/25/2022 | 619.42% | 瑞士信貸 | $15→$10 | 維護 | 跑贏大盤 |
| 11/08/2021 | 979.14% | 瑞士信貸 | →$15 | 開始承保 | →跑贏大盤 |
| 2021/10/21 | - | 威廉·布萊爾 | 開始承保 | →跑贏大盤 | |
| 10/20/2021 | 1266.91% | 蒙特利爾銀行資本 | →$19 | 開始承保 | →跑贏大盤 |
| 10/13/2021 | 1410.79% | 奧本海默 | →$21 | 開始承保 | →跑贏大盤 |
What is the target price for Jasper Therapeutics (JSPR)?
Jasper Treeutics(JSPR)的目標價格是多少？
The latest price target for Jasper Therapeutics (NASDAQ: JSPR) was reported by Credit Suisse on August 14, 2023. The analyst firm set a price target for $4.00 expecting JSPR to rise to within 12 months (a possible 187.77% upside). 19 analyst firms have reported ratings in the last year.
瑞士信貸於2023年8月14日報告了賈斯珀治療公司(納斯達克：JSPR)的最新目標價。這家分析公司將目標價定為4美元，預計JSPR將在12個月內上漲至(可能上漲187.77%)。去年有19家分析公司公佈了評級。
What is the most recent analyst rating for Jasper Therapeutics (JSPR)?
賈斯珀治療公司(JSPR)的最新分析師評級是什麼？
The latest analyst rating for Jasper Therapeutics (NASDAQ: JSPR) was provided by Credit Suisse, and Jasper Therapeutics reiterated their outperform rating.
嘉士伯治療公司(納斯達克代碼：JSPR)的最新分析師評級由瑞士信貸提供，嘉士伯治療公司重申其表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for Jasper Therapeutics (JSPR)?
Jasper治療公司(JSPR)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Jasper Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Jasper Therapeutics was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Jasper Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Jasper治療公司的上一次評級是在2023年8月14日提交的，所以你應該預計下一次評級將在2024年8月14日左右提供。
Is the Analyst Rating Jasper Therapeutics (JSPR) correct?
分析師對Jasper Treeutics(JSPR)的評級正確嗎？
While ratings are subjective and will change, the latest Jasper Therapeutics (JSPR) rating was a reiterated with a price target of $0.00 to $4.00. The current price Jasper Therapeutics (JSPR) is trading at is $1.39, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的Jasper治療公司(JSPR)的評級被重申，目標價在0.00美元到4.00美元之間。賈斯珀治療公司(JSPR)目前的交易價格為1.39美元，在分析師的預測範圍內。